[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pelvic-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pelvic-neoplasm":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100640485","postoperative-gi-dysfunction-and-nutrition-in-malnourished-cancer-surgery-patients-100640485",false,"NCT07622888","Postoperative GI Dysfunction and Nutrition in Malnourished Cancer Surgery Patients","Gastrointestinal Dysfunction, Nutritional Status, and Delirium in the Early Postoperative Period in Oncologic Surgical Patients With Pre-existing Malnutrition: A Prospective Two-Center Observational Cohort Study","GIDNUT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed malignant tumor of the abdomen or pelvis with planned radical or cytoreductive surgery.\n* Baseline malnutrition defined as NRS2002 ≥ 3 and at least one phenotypic and one etiologic GLIM criterion.\n* Expected postoperative hospitalization ≥ 7 days.\n* Ability to undergo baseline cognitive and nutritional assessments (MoCA, NRS2002, GLIM, PG-SGA) prior to surgery.\n* Signed informed consent for participation and data collection.\n\nExclusion Criteria:\n\n* Severe decompensated hepatic or renal failure rendering surgery infeasible.\n* Documented preexisting severe cognitive impairment or dementia precluding valid postoperative cognitive\u002Fdelirium assessment (e.g., MoCA \\\u003C 18 or documented dementia).\n* Pregnancy or breastfeeding.\n* Participation in another interventional randomized clinical trial within the prior 30 days that could confound outcomes.\n* Inability to ensure postoperative follow-up or reliable data collection (planned transfer without access, loss of contact).","ALL","18 Years",{"count":20,"type":21},120,"ESTIMATED","OBSERVATIONAL","This is a prospective two-center observational cohort study in adult patients undergoing major abdominal and\u002For pelvic oncologic surgery with pre-existing malnutrition. The study describes the course of postoperative gastrointestinal dysfunction and evaluates whether real-world exposure to parenteral serotonin as part of routine postoperative care is associated with a higher proportion of patients whose gastrointestinal dysfunction regresses to LIFE score less than or equal to 1 by postoperative day 5 (plus or minus 1 day), compared with patients not exposed to serotonin.\n\nAll treatment decisions, including the use of parenteral serotonin, metoclopramide, neostigmine, nutritional support, and other postoperative management, are made solely by the treating physicians in accordance with routine clinical practice. The protocol does not assign, randomize, require, or restrict any drug treatment; it records real-world care, daily LIFE assessments during postoperative days 1 through 7, nutritional status measures, body composition where available, delirium screening, complications, length of stay, and mortality.",[25,26,27,28,29],"Gastrointestinal Dysfunction","Malnutrition","Delirium - Postoperative","Abdominal Neoplasm","Pelvic Neoplasm","NOT_YET_RECRUITING","2026-05-31",{"date":33,"type":34},"2026-06-03","ACTUAL",{"date":36,"type":21},"2026-10-01",{"date":38,"type":21},"2029-03-01",{"name":40,"class":41},"Arma Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":57,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":42},"100566170","phase-3-bladder-full-or-empty-for-pelvic-radiation-therapy-100566170","NCT06651697","BladdEr Full OR Empty for Pelvic Radiation Therapy","BEFORE","Inclusion Criteria:\n\n* Provision of signed and dated informed consent form\n* Stated willingness to comply with all study procedures and availability for the duration of the study\n* Persons, aged at least 18 years\n* Deemed eligible to undergo curative intent radiation therapy for primary GU, GI, or Gyn malignancy of the pelvis.\n* For participants able to become pregnant: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation\n* For participants able to cause a pregnancy: use of condoms or other methods to ensure effective contraception with partner\n\nExclusion Criteria:\n\n* Pregnancy\n* Tumor invading the bladder, as judged by the enrolling physician based on available clinical information\n* Contraindications to radiotherapy, including Crohn's disease and active connective tissue disorders such as scleroderma or uncontrolled lupus\n* Prior radiation therapy to an area requiring treatment in the present study",{"count":51,"type":21},300,"INTERVENTIONAL",[54],"PHASE3","The present study evaluates empty and full bladder protocols for radiation therapy of genitourinary (GU), gynecological (Gyn), and gastrointestinal (GI) malignancies of the pelvis.",[29],[58,59,60],"malignancy of the pelvis","bladder","radiation therapy","RECRUITING","2026-02-15",{"date":64,"type":34},"2026-02-17",{"date":66,"type":34},"2024-11-19",{"date":68,"type":21},"2029-12",{"name":70,"class":71},"University of California, San Diego","OTHER",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":17,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":42},"100485767","exploiting-the-gut-microbiota-and-its-metabolites-in-pelvic-cancer-100485767","NCT05605353","Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer","Inclusion Criteria:\n\n1. Patients willing to consent\n2. Any patient who is being treated in NHS Grampian for a pelvic cancer (Colorectal, urological or gynaecological) above 16 years of age\n\nExclusion Criteria:\n\n1. patients who are not willing to consent to be involved\n2. Malignancies from other sources or anatomical locations\n3. Patients who lack the understanding of the study to obtain appropriate levels of consen","16 Years","99 Years",{"count":81,"type":21},450,"The large intestine is the last part of the digestive tract. It absorbs water and dietary substances. However, it is also where most of our bacteria are resident. These bacteria are important for our health and influence many different diseases, including Colon Cancer, Ulcerative Colitis and Crohn's disease. The gut bacteria can also potentially influence responses to treatments in other cancers by helping to change the responses to radiotherapy and chemotherapy. The interactions between these bacteria and the rest of our cells are only now becoming understood and there is little research on the interactions between these bacteria and cancer radiotherapy treatments in pelvic cancer.\n\nWe will therefore explore this in more detail. We will ask for samples of the patient's poo before their treatment for pelvic cancers. This will include patients with bladder, prostate, cervical, ovarian, womb or colorectal cancers. By doing so we will be able to compare the profile of gut bacteria with responses to treatments, thereby increasing our understanding of the colonic bacteria.\n\nTo do this we process the poo specimens to remove the bacterial genetic material (DNA) of the bacteria and process it on a machine to read the genetic code and also study the metabolites that they will produce. We can then make a direct comparison between different samples of the relative numbers of different bacteria present. In some cases, we will compare this to metabolites and inflammatory and immune markers identified in a blood sample. This work might help future patients by determining what are the best bacteria to have in the colon during cancer treatments. These could potentially be given to patients, before their cancer treatment, in the form of probiotic medications, should there be an improvement demonstrated in our research. Alternatively we could alter the patients' intakes of specific dietary fibres to boost these bacteria specifically.",[29],"2023-05-12",{"date":86,"type":34},"2023-05-16",{"date":88,"type":34},"2023-03-01",{"date":90,"type":21},"2029-05-31",{"name":92,"class":71},"University of Aberdeen"]